Which antidepressants are associated with QT prolongation and should be avoided when used with concomitant atypical antipsychotics?

Which antidepressants are associated with QT prolongation and should be avoided when used with concomitant atypical antipsychotics?

• A. Fluoxetine, Sertraline
• B. Citalopram, Escitalopram
• C. Bupropion, Mirtazapine
• D. Venlafaxine, Paroxetine

Answer: (B)

QT prolongation is a key safety concern when combining antidepressants with atypical antipsychotics, because both drug classes can affect cardiac repolarization and raise the risk of torsades de pointes. The strongest, most consistent association with QT prolongation among antidepressants is seen with citalopram and escitalopram, and this risk increases at higher doses. Because of the additive effect on the QT interval, these two should be avoided when an atypical antipsychotic is also being used. Other antidepressants generally have less effect on QT and are often preferred in this situation, such as fluoxetine or sertraline, or non-QT–prolonging options like bupropion or mirtazapine. If these agents are used, monitor the patient with ECG and address risk factors like electrolyte disturbances or bradycardia.

QT prolongation is a key safety concern when combining antidepressants with atypical antipsychotics, because both drug classes can affect cardiac repolarization and raise the risk of torsades de pointes. The strongest, most consistent association with QT prolongation among antidepressants is seen with citalopram and escitalopram, and this risk increases at higher doses. Because of the additive effect on the QT interval, these two should be avoided when an atypical antipsychotic is also being used. Other antidepressants generally have less effect on QT and are often preferred in this situation, such as fluoxetine or sertraline, or non-QT–prolonging options like bupropion or mirtazapine. If these agents are used, monitor the patient with ECG and address risk factors like electrolyte disturbances or bradycardia.